Tenet Healthcare rated Buy after strong Q2 results and margin growth, with attractive valuation and growth prospects.

Tenet Healthcare received a Buy rating following robust Q2 financial results, including a 22.3% rise in adjusted EBITDA and a 52.2% increase in EPS. The hospital segment's EBITDA margin jumped to 18%, supporting an upward revision of 2026 guidance. United Surgical Partners International (USPI) remains a key growth driver with a 39% EBITDA margin, though surgical volumes declined, making volume recovery a critical factor for future gains. Strong free cash flow yield of around 13% allows for aggressive share buybacks and acquisitions, but investors should watch hospital margin sustainability and USPI volume trends in Q3.

Tenet Healthcare Corporation (THC) trades at USD 267.90 on Pluang as of Oct 22, 2026 17:12 WIB, slightly down 0.46% for the day. The stock holds a market cap of $21.67 billion and a 52-week high of $280.77, indicating strong investor interest despite recent minor dips. This trading context complements the news of improving hospital margins and robust Q2 results, highlighting ongoing market attention to THC's operational performance and growth prospects.